Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin’s Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809
Richard I. Fisher(University of Rochester), Thomas P. Miller, Ellen R. Gaynor(University of Oklahoma Health Sciences Center), Joseph M. Unger(Fred Hutch Cancer Center), Vivek Roy(Jacksonville College), Bruce W. Dana(University of Oklahoma Health Sciences Center), Stanley P. Balcerzak(University of Oklahoma Health Sciences Center), Jeffrey D. Forman(Wayne State University), Carl R. Kjeldsberg(University of Oklahoma Health Sciences Center), Michael LeBlanc(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 81
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k